Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma

Authors

Cinzia Federico, Washington University School of Medicine in St. Louis
Kinan Alhallak, Washington University School of Medicine in St. Louis
Jennifer Sun, Washington University School of Medicine in St. Louis
Kathleen Duncan, Washington University School of Medicine in St. Louis
Feda Azab, Washington University School of Medicine in St. Louis
Gail P. Sudlow, Washington University School of Medicine in St. Louis
Pilar de la Puente, Washington University School of Medicine in St. Louis
Barbara Muz, Washington University School of Medicine in St. Louis
Vaishali Kapoor, Washington University School of Medicine in St. Louis
Luna Zhang, Washington University School of Medicine in St. Louis
Fangzheng Yuan, Washington University School of Medicine in St. Louis
Matea Markovic, Washington University School of Medicine in St. Louis
Joseph Kotsybar, Washington University School of Medicine in St. Louis
Katherine Wasden, Washington University School of Medicine in St. Louis
Nicole Guenthner, Washington University School of Medicine in St. Louis
Shannon Gurley, Washington University School of Medicine in St. Louis
Justin King, Washington University School of Medicine in St. Louis
Daniel Kohnen, Washington University School of Medicine in St. Louis
Noha N. Salama, St. Louis College of Pharmacy
Dinesh Thotala, Washington University School of Medicine in St. Louis
Dennis E. Hallahan, Washington University School of Medicine in St. Louis
Ravi Vij, Washington University School of Medicine in St. Louis
John F. DiPersio, Washington University School of Medicine in St. Louis
Samuel Achilefu, Washington University in St. Louis
Abdel Kareem Azab, Washington University School of Medicine in St. Louis

Document Type

Article

Publication Title

Nature Communications

Abstract

Drug resistance and dose-limiting toxicities are significant barriers for treatment of multiple myeloma (MM). Bone marrow microenvironment (BMME) plays a major role in drug resistance in MM. Drug delivery with targeted nanoparticles have been shown to improve specificity and efficacy and reduce toxicity. We aim to improve treatments for MM by (1) using nanoparticle delivery to enhance efficacy and reduce toxicity; (2) targeting the tumor-associated endothelium for specific delivery of the cargo to the tumor area, and (3) synchronizing the delivery of chemotherapy (bortezomib; BTZ) and BMME-disrupting agents (ROCK inhibitor) to overcome BMME-induced drug resistance. We find that targeting the BMME with P-selectin glycoprotein ligand-1 (PSGL-1)-targeted BTZ and ROCK inhibitor-loaded liposomes is more effective than free drugs, non-targeted liposomes, and single-agent controls and reduces severe BTZ-associated side effects. These results support the use of PSGL-1-targeted multi-drug and even non-targeted liposomal BTZ formulations for the enhancement of patient outcome in MM.

DOI

10.1038/s41467-020-19932-1

Publication Date

12-1-2020

Share

COinS